NO20055652L - Laktatinneholdende farmasoytisk preparat og anvendelse av dette - Google Patents

Laktatinneholdende farmasoytisk preparat og anvendelse av dette

Info

Publication number
NO20055652L
NO20055652L NO20055652A NO20055652A NO20055652L NO 20055652 L NO20055652 L NO 20055652L NO 20055652 A NO20055652 A NO 20055652A NO 20055652 A NO20055652 A NO 20055652A NO 20055652 L NO20055652 L NO 20055652L
Authority
NO
Norway
Prior art keywords
lactate
millimoles per
pharmaceutical preparation
liters
containing pharmaceutical
Prior art date
Application number
NO20055652A
Other languages
English (en)
Other versions
NO20055652D0 (no
Inventor
Xavier M Leverve
Mustafa Iqbal
Original Assignee
Innogene Kalbiotech Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogene Kalbiotech Pte Ltd filed Critical Innogene Kalbiotech Pte Ltd
Publication of NO20055652D0 publication Critical patent/NO20055652D0/no
Publication of NO20055652L publication Critical patent/NO20055652L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)

Abstract

Foreliggende oppfinnelse gjelder et farmasøytisk preparat inneholdende fra 250-2400 millimol pr. liter av laktat eller melkesyre, fra 2-10 millimol pr. liter av kaliumkation og om ønskelig fra 2-5 millimol pr. liter av kalsiumkation. Oppfinnelsen gjelder også farmasøytiske anvendelser av dette preparat. Oppfinnelsen gjelder også farmasøytiske anvendelser av et preparat med en melkesyre- eller laktatkonsentrasjon på mellom 250 og 2400 millimol pr. liter.
NO20055652A 2003-05-01 2005-11-30 Laktatinneholdende farmasoytisk preparat og anvendelse av dette NO20055652L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ID20030213 2003-05-01
PCT/SG2004/000066 WO2004096204A1 (en) 2003-05-01 2004-03-22 Lactate containing pharmaceutical composition and uses thereof

Publications (2)

Publication Number Publication Date
NO20055652D0 NO20055652D0 (no) 2005-11-30
NO20055652L true NO20055652L (no) 2006-02-01

Family

ID=33397627

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055652A NO20055652L (no) 2003-05-01 2005-11-30 Laktatinneholdende farmasoytisk preparat og anvendelse av dette

Country Status (31)

Country Link
US (1) US20080125488A1 (no)
EP (2) EP1759695A1 (no)
JP (1) JP5037937B2 (no)
KR (1) KR101076059B1 (no)
CN (1) CN1777416B (no)
AR (1) AR043670A1 (no)
AT (1) ATE340568T1 (no)
AU (1) AU2004233904B2 (no)
BR (1) BRPI0409867A (no)
CA (1) CA2523740C (no)
CY (1) CY1105880T1 (no)
DE (1) DE602004002585T2 (no)
DK (1) DK1617834T3 (no)
EA (2) EA010948B1 (no)
ES (1) ES2274438T3 (no)
HK (1) HK1085942A1 (no)
IL (1) IL171721A (no)
MA (1) MA27845A1 (no)
MX (1) MXPA05011532A (no)
MY (1) MY140382A (no)
NO (1) NO20055652L (no)
NZ (1) NZ543201A (no)
PL (1) PL1617834T3 (no)
PT (1) PT1617834E (no)
SG (1) SG160217A1 (no)
SI (1) SI1617834T1 (no)
TN (1) TNSN05275A1 (no)
TW (1) TWI290045B (no)
UA (1) UA86937C2 (no)
WO (1) WO2004096204A1 (no)
ZA (1) ZA200509684B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006341414A1 (en) * 2006-04-03 2007-10-11 Innogene Kalbiotech Pte Ltd Lactate and calcium containing pharmaceutical composition and uses thereof
EP2679222A1 (en) 2007-03-30 2014-01-01 Laccure Ab Use of oligomers of lactic acid in the treatment of gynaecological infections
RU2577698C2 (ru) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
MX2011009956A (es) * 2009-03-26 2012-01-27 Pulmatrix Inc Formulaciones de citrato de calcio y lactato de calcio para la modificacion de las propiedades biofisicas del revestimiento mucosal.
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
JP5877201B2 (ja) 2010-08-30 2016-03-02 パルマトリックス，インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
DK2621488T3 (en) 2010-09-29 2019-03-04 Pulmatrix Operating Co Inc CATIONIC DRY POWDER
CN103228273B (zh) 2010-09-29 2017-04-05 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
ES2396650B2 (es) * 2011-07-21 2013-07-16 Universidad Complutense De Madrid Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal.
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
KR102200176B1 (ko) 2012-05-08 2021-01-11 에어로믹스, 인코포레이티드 신규 방법
WO2014021718A1 (en) * 2012-08-01 2014-02-06 Purac Biochem B.V. Lactate powder and method for the preparation thereof
US9897609B2 (en) 2012-10-25 2018-02-20 Run Them Sweet, LLC Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs
US9232815B2 (en) 2012-10-25 2016-01-12 Run Them Sweet, LLC Blood lactate range targets and nutritional formulations and protocols to support patients
US9808031B2 (en) 2012-10-25 2017-11-07 Run Them Sweet Llc Systems and methods to estimate nutritional needs of human and other patients
EP2754356A1 (en) 2013-01-15 2014-07-16 Purac Biochem N.V. Improved nisin production process
EP2769630B1 (en) 2013-02-26 2016-04-27 Purac Biochem N.V. Improved nisin production process
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
WO2015182815A1 (ko) * 2014-05-26 2015-12-03 한국생명공학연구원 Ndrg3 발현 또는 활성 촉진제를 유효성분으로 함유하는 허혈성 질환 예방 및 치료용 약학적 조성물
CA3026631C (en) 2016-07-07 2024-03-26 Dsm Ip Assets B.V. Process for obtaining a rapeseed protein isolate and protein isolate thereby obtained
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
WO2020163654A1 (en) * 2019-02-06 2020-08-13 Paul Leo Mcgrane Biologically modified vascular grafts for improved bypass surgery outcomes
WO2021150259A1 (en) * 2020-01-24 2021-07-29 Barkey Daniel Q Compositions and methods for weight loss
WO2023114375A2 (en) * 2021-12-16 2023-06-22 Alveolus Bio, Inc. Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987003808A1 (en) * 1985-12-18 1987-07-02 Veech Richard L Fluid therapy with l-lactate and/or pyruvate anions
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
JPH05255092A (ja) * 1992-03-17 1993-10-05 Kyowa Hakko Kogyo Co Ltd 腸管洗浄用組成物
RU2142282C1 (ru) * 1993-06-04 1999-12-10 Биотайм, Инк Раствор кровезаменителя на водной основе и способ его получения
US6306828B1 (en) * 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
JPH0940554A (ja) * 1995-08-03 1997-02-10 Nissho Corp グルタミンを含む輸液及びその製造方法
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
US6436444B1 (en) * 1997-09-26 2002-08-20 Ecolab Inc. Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
RU2136293C1 (ru) * 1998-08-04 1999-09-10 Открытое акционерное общество "Биохимик" Способ получения заменителя плазмы крови

Also Published As

Publication number Publication date
CN1777416A (zh) 2006-05-24
MXPA05011532A (es) 2006-05-31
WO2004096204A1 (en) 2004-11-11
PL1617834T3 (pl) 2007-02-28
SG160217A1 (en) 2010-04-29
TW200423923A (en) 2004-11-16
KR101076059B1 (ko) 2011-10-21
DK1617834T3 (da) 2007-02-05
TWI290045B (en) 2007-11-21
DE602004002585D1 (de) 2006-11-09
JP2006525324A (ja) 2006-11-09
JP5037937B2 (ja) 2012-10-03
EA200801073A1 (ru) 2008-08-29
AU2004233904B2 (en) 2009-11-12
KR20050119701A (ko) 2005-12-21
EA010948B1 (ru) 2008-12-30
EP1617834B1 (en) 2006-09-27
EA013846B1 (ru) 2010-08-30
EP1759695A1 (en) 2007-03-07
BRPI0409867A (pt) 2006-05-16
AR043670A1 (es) 2005-08-03
AU2004233904A1 (en) 2004-11-11
CA2523740A1 (en) 2004-11-11
NO20055652D0 (no) 2005-11-30
HK1085942A1 (en) 2006-09-08
ZA200509684B (en) 2007-03-28
NZ543201A (en) 2007-05-31
EP1617834A1 (en) 2006-01-25
MY140382A (en) 2009-12-31
DE602004002585T2 (de) 2007-10-25
US20080125488A1 (en) 2008-05-29
TNSN05275A1 (en) 2007-07-10
UA86937C2 (ru) 2009-06-10
SI1617834T1 (sl) 2007-02-28
ES2274438T3 (es) 2007-05-16
CA2523740C (en) 2012-05-15
CN1777416B (zh) 2012-11-07
CY1105880T1 (el) 2011-02-02
PT1617834E (pt) 2007-01-31
ATE340568T1 (de) 2006-10-15
EA200501675A1 (ru) 2006-06-30
IL171721A (en) 2012-05-31
MA27845A1 (fr) 2006-04-03

Similar Documents

Publication Publication Date Title
NO20055652L (no) Laktatinneholdende farmasoytisk preparat og anvendelse av dette
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
BR0215517A (pt) Composição anti-séptica, e, métodos para desinfetar tecido e para produzir uma composição anti-séptica
AU2003275958A1 (en) Muteins of tear lipocalin
SE0301010D0 (sv) Novel compounds
HUP0300342A2 (hu) Carvedilol hidrofil molekuláris diszperziós oldatait tartalmazó készítmények, eljárás az előállításukra és alkalmazásuk
HUP0401144A2 (hu) Enterális tápszerkészítmények
IL168836A (en) Pyrimidine-sulfamides and their use as endothelin receptor antagonist
HUP0301124A2 (hu) Elszíneződésre nem hajlamos. minoxidil-tartalmú kompozíció és eljárás minoxidiltartalmú kompozíció elszíneződésének megakadályozására
ATE528990T1 (de) Desinfektions- und entkeimungsmittel
HUP0401140A2 (en) Disinfectant solution based on sodium hypochlorite, and process for preparing it
ATE408022T1 (de) Ermittlung des patientenbezogenen kariesrisikos
NO20076405L (no) Anvendelse av 24-nor-UDCA
AU2003273728A1 (en) A new crystalline form of the sodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid
ATE494894T1 (de) Viruzide wirkungen von einer zubereitung enthaltend cetylpyridiniumchlorid und zitronensäure
WO2004039326A3 (en) Propofol with cysteine
WO2003086335A8 (en) Hair care composition for restoring the elasticity of hair
GB0511269D0 (en) Sustained release preparation of pro-insulin C-peptide
HUP0301864A2 (hu) Fenoláttartalmú, alacsony fagyáspontú készítmény
DE50312414D1 (de) Kompositmaterialien aus calciumverbindungen und glucuronsäurehaltigen polysacchariden
DK1409449T3 (da) Alpha-ketoglutarater af aktive ingredienser og sammensætninger omfattende disse
DE60311351D1 (de) Verwendung von Zeoliten zur Herstellung oraler Zubereitungen zur Behandlung von Vergiftung
NO20061290L (no) Nye forbindelser
MY164917A (en) Lactate containing pharmaceutical composition and uses thereof
MXPA05008860A (es) Composiciones farmaceuticas estabilizadas de safingol y metodos para utilizar las mismas.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application